Clinical use of markers of bone turnover in metastatic bone disease (original) (raw)

• Rubens RD (2000) Clinical aspects of bone metastases. In Tumor Bone Diseases and Osteoporosis in Cancer Patients, 85–96 (Ed Body J-J) New York: Marcel Dekker
  Google Scholar
• Lipton A et al. (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomised placebo-controlled trials. Cancer 88: 1082–1090
  Article CAS PubMed Google Scholar
• Ross JR et al. (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327: 469–472
  Article CAS PubMed PubMed Central Google Scholar
• Bubley G et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate Specific Antigen Working Group. J Clin Oncol 18: 3461–3477
  Article Google Scholar
• Yoneda T and Hiraga T (2005) Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328: 679–687
  Article CAS PubMed Google Scholar
• Chung LW et al. (2005) Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol 173: 10–20
  Article PubMed Google Scholar
• Seibel MJ (2003) Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 32: 83–113
  Article CAS PubMed Google Scholar
• Fukumitsu N et al. (2002) Correlation of urine type I collagen-cross-linked N telopeptide levels with bone scintigraphic results in prostate cancer patients. Metabolism 51: 814–818
  Article CAS PubMed Google Scholar
• Meijer WG et al. (2003) Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 44: 184–191
  PubMed Google Scholar
• Ebert W et al. (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24: 3193–3201
  CAS PubMed Google Scholar
• Springer IN et al. (2003) Follow-up of collagen crosslink excretion in patients with oral squamous cell carcinoma and analysis of tissue samples. Br J Cancer 89: 1722–1728
  Article CAS PubMed PubMed Central Google Scholar
• Francini G et al. (1990) Comparison between CEA, TPA, CA 15-3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer. Int J Biol Markers 5: 65–72
  Article CAS PubMed Google Scholar
• Berruti A et al. (1999) Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45: 1240–1247
  CAS PubMed Google Scholar
• Kanakis I et al. (2004) Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. Pharm Biomed Anal 34: 827–832
  Article CAS Google Scholar
• Oremek GM et al. (2003) Diagnostic value of bone and tumour markers in patients with malignant diseases. Anticancer Res 23: 987–990
  CAS PubMed Google Scholar
• Lorente JA et al. (1999) Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 26: 625–632
  Article CAS PubMed Google Scholar
• Wymenga LF et al. (2001) Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. Br J Urol 88: 231–235
  Article CAS Google Scholar
• Bombardieri E et al. (1997) Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer? Eur J Nucl Med 24: 1349–1355
  Article CAS PubMed Google Scholar
• Wada S et al. (1993) Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy. Int Med 32: 611–618
  Article CAS Google Scholar
• Bataille R et al. (1990) Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 66: 167–172
  Article CAS PubMed Google Scholar
• Mejjad O et al. (1996) Osteocalcin is not a marker of progress in multiple myeloma. Eur J Haematol 56: 30–34
  Article CAS PubMed Google Scholar
• Carlson K et al. (1999) Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 62: 300–306
  Article CAS PubMed Google Scholar
• Berenson JR et al. (2001) A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 7: 478–485
  CAS PubMed Google Scholar
• Tian E et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483–2494
  Article CAS PubMed Google Scholar
• Jukkola A et al. (1997) Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 57: 5517–5520
  CAS PubMed Google Scholar
• Ylisirnio S et al. (1999) Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 19: 5577–5581
  CAS PubMed Google Scholar
• Koizumi M et al. (2003) Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23: 4095–4099
  CAS PubMed Google Scholar
• Paterson CR et al. (1991) Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 64: 884–886
  Article CAS PubMed PubMed Central Google Scholar
• Pecherstorfer M et al. (1995) The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80: 97–103
  CAS PubMed Google Scholar
• Alatas F et al. (2002) Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem 35: 293–296
  Article CAS PubMed Google Scholar
• Behrens P et al. Pyridinoline cross-links as markers for primary and secondary bone tumors. Scand J Clin Lab Invest 63: 37–44
• Motellon JL et al. (2000) Relationship of plasma bone cytokines with hypercalcemia in cancer patients. Clin Chim Acta 302: 59–68
  Article CAS PubMed Google Scholar
• Pecherstorfer M et al. (1997) Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 90: 3743–3750
  CAS PubMed Google Scholar
• Ulrich U et al. (2001) Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch Gynecol Obstet 264: 186–190
  Article CAS PubMed Google Scholar
• Wada N et al. (2001) Evaluation of bone metabolic markers in breast cancer with bone metastasis. Breast Cancer 8: 131–137
  Article CAS PubMed Google Scholar
• Costa L et al. (2002) Prospective evaluation of the peptide-bound collagen type I crosslinks N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20: 850–856
  Article CAS PubMed Google Scholar
• Kiuchi K et al. (2002) Cross-linked collagen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer. Oncol Rep 9: 595–598
  CAS PubMed Google Scholar
• Cloos PA et al. (2004) An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 50: 279–289
  CAS PubMed Google Scholar
• Koizumi M et al. (2002) Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J Urol 167: 1863–1866
  Article PubMed Google Scholar
• Noguchi M and Noda S (2001) Pyridinoline cross-linked carboxy terminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. J Urol 166: 1106–1110
  Article CAS PubMed Google Scholar
• de la Piedra C et al. (2003) Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331: 45–53
  Article CAS PubMed Google Scholar
• Nabeya Y et al. (2002) Serum cross-linked carboxy terminal telopeptide of type I collagen (ICTP) as a prognostic tumor marker in patients with esophageal squamous cell carcinoma. Cancer 94: 940–949
  Article CAS PubMed Google Scholar
• Capeller B et al. (2003) Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 23: 1011–1015
  CAS PubMed Google Scholar
• Chao TY et al. (2004) Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J Biomed Sci 11: 511–516
  Article CAS PubMed Google Scholar
• Halleen JM et al. (2001) Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47: 597–600
  CAS PubMed Google Scholar
• Jain A et al. (2002) Three SIBLINGs enhance Factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J Biol Chem 277: 13700–13708
  Article CAS PubMed Google Scholar
• Seibel MJ et al. (1996) Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81: 3289–3294
  CAS PubMed Google Scholar
• Bellahcene A et al. (1996) Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69: 350–353
  Article CAS PubMed Google Scholar
• Fedarko et al. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060–4066
  CAS PubMed Google Scholar
• Woitge HW et al. (2001) Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma. Br J Cancer 84: 344–351
  Article CAS PubMed PubMed Central Google Scholar
• Woitge HW et al. (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14: 792–801
  Article CAS PubMed Google Scholar
• Brown JE et al. (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97: 59–69
  Article CAS PubMed Google Scholar
• Vinholes J et al. (1999) Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 80: 221–228
  Article CAS PubMed PubMed Central Google Scholar
• Coleman RE et al. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925–4935
  Article CAS PubMed Google Scholar
• Jukkola A et al. (2001) Postoperative PINP in serum reflects metastatic potential and poor survival in node-positive breast cancer. Anticancer Res 21: 2873–2876
  CAS PubMed Google Scholar
• Ali SM et al. (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15: 455–459
  Article CAS PubMed Google Scholar
• Berruti A et al. (2002) Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. Int J Biol Markers 17: 244–252
  Article CAS PubMed Google Scholar
• Kylmälä T et al. (1995) Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 71: 1061–1064
  Article PubMed PubMed Central Google Scholar
• Petrioli R et al. (2004) Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases. Urology 63: 321–326
  Article PubMed Google Scholar
• Seibel MJ et al. (2002) Markers of bone turnover do not predict bone metastases in breast cancer. Clin Lab 48: 583–588
  CAS PubMed Google Scholar
• Seibel MJ et al. (2002) Long-term variability of markers of bone turnover in patients with breast cancer. Clin Lab 48: 576–582
  Google Scholar
• De Pinieux G et al. (2001) Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases. J Urol 166: 1924–1930
  Article CAS PubMed Google Scholar
• Diel I et al. (1999) Serum bone sialoprotein in patients with primary breast cancer as a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5: 3914–3919
  CAS PubMed Google Scholar
• Fonseca R et al. (2000) Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients. Br J Haematol 109: 24–29
  Article CAS PubMed Google Scholar
• Abildgaard N et al. (1998) Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 61: 128–134
  Article CAS PubMed Google Scholar
• Jagdev SP et al. (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12: 1433–1438
  Article CAS PubMed Google Scholar
• Terpos E et al. (2000) Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 65: 331–336
  Article CAS PubMed Google Scholar
• Body JJ et al. (1997) Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75: 408–412
  Article CAS PubMed PubMed Central Google Scholar
• Lipton A et al. (1998) Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 34: 2021–2026
  Article CAS PubMed Google Scholar
• Martinetti A et al. (2002) Serum levels of tartrate resistant acid phosphatase-5b in breast cancer patients treated with pamidronate. Int J Biol Markers 17: 253–258
  Article CAS PubMed Google Scholar
• Carlson K et al. (1992) Serum osteocalcin concentrations in patients with multiple myeloma: correlation with disease stage and survival. J Intern Med 231: 133–137
  Article CAS PubMed Google Scholar
• Magnusson P et al. (1998) Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain. Clin Chem 44: 1621–1628
  CAS PubMed Google Scholar
• Koizumi M et al. (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87: 348–3451
  Article CAS PubMed Google Scholar
• Blomqvist C et al. (1987) The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. Cancer 60: 2907–2912
  Article CAS PubMed Google Scholar
• Vinholes JJ et al. (1997) Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 8: 1243–1250
  Article CAS PubMed Google Scholar
• Luftner D et al. (2003) Normalisation of biochemical markers of bone formation correlates with clinical benefit from therapy in metastatic breast cancer. Anticancer Res 23: 1017–1026
  CAS PubMed Google Scholar
• Chen T et al. (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42: 1228–1236
  Article CAS PubMed Google Scholar
• Brown JE et al. (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89: 2031–2037
  Article CAS PubMed PubMed Central Google Scholar
• Marttunen MB et al. (1999) Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer. Calcif Tissue Int 65: 365–368
  Article CAS PubMed Google Scholar
• Kenny AM et al. (1995) The short term effects of tamoxifen on bone turnover in older women. J Clin Endocrinol Metab 80: 3287–3291
  CAS PubMed Google Scholar
• Li F et al. (1993) Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. Eur J Clin Invest 23: 566–571
  Article CAS PubMed Google Scholar
• Noguchi M et al. (2003) Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. Urology 61: 993–998
  Article PubMed Google Scholar
• Diamond T et al. (1997) Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 97: 641–648
  Article CAS PubMed Google Scholar
• Piovesan A et al. (1997) Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease. Calcif Tissue Int 61: 362–369
  Article CAS PubMed Google Scholar
• Clark RE et al. (2000) Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 96: 2697–2702
  CAS PubMed Google Scholar
• Nguyen T et al. Variability of bone marker measurements. In Dynamics of Bone and Cartilage Metabolism, (Eds Seibel MJ et al.) San Diego: Elsevier/Academic, in press
• Meier C et al. Monitoring of anti-resorptive treatment. In Dynamics of Bone and Cartilage Metabolism, (Eds Seibel MJ et al.) San Diego: Elsevier/Academic, in press
• Delmas PD et al. (2000) The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11 (Suppl 6): S2–S17
  Article PubMed Google Scholar